TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39562219

Group type: EXPERIMENTAL
Intervention: Extended bleaching tray (3 mm)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nonextended bleaching tray (1 mm)
Number of subjects: 72
Study: 39562382

Group type: EXPERIMENTAL
Intervention: Fucoidan
Number of subjects: 0
Study: 39562414

Group type: EXPERIMENTAL
Intervention: Presence of Methanobrevibacter (Archaea)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High TMAO plasma levels
Number of subjects: 25
Study: 39562421

Group type: EXPERIMENTAL
Intervention: Indocyanine green
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluorescein
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multispectral imaging
Number of subjects: 16
Study: 39562502

Group type: EXPERIMENTAL
Intervention: Lower chromosome fragility
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Mutations leading to mutant FANCA protein expression (genetic hypomorphism)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Biallelic mutations in FANCD2 (mainly hypomorphic mutations)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Biallelic mutations in FANCG
Number of subjects: 227
Study: 39563035

Group type: EXPERIMENTAL
Intervention: ARI0003 (anti-CD19/BCMA CAR-T cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: anti-CD19 CAR-T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: anti-CD19/CD20 or anti-CD19/CD22 dual targeting
Number of subjects: 0
Study: 39563094

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399
Study: 39563102

Group type: EXPERIMENTAL
Intervention: 2-Minute Step Test (2MST)
Number of subjects: 55
Study: 39563227

Group type: EXPERIMENTAL
Intervention: Any human papillomavirus infection at mid-gestation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus infection at mid-gestation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Human papillomavirus genotype 16 infection at mid-gestation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Multiple genotype infections at mid-gestation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Persisting infections during pregnancy
Number of subjects: 950
Study: 39563247

Group type: EXPERIMENTAL
Intervention: Couples Health Project (CHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Couples HIV testing and counseling (CHTC)
Number of subjects: 0
Study: 39563248

Group type: EXPERIMENTAL
Intervention: TES: Vira smartphone app
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control: Mood Education mobile app (ME)
Number of subjects: 130
Study: 39563299

Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme (THP) intervention
Number of subjects: 0
Study: 39563311

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise using elastic bands (performed exercise dose measured in repetitions/week)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise using elastic bands
Number of subjects: 94
Study: 39563319

Group type: EXPERIMENTAL
Intervention: MOP-facilitated MARPE (MMG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: MARPE without MOP (NMG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (MMG and NMG)
Number of subjects: 48
Study: 39563407

Group type: EXPERIMENTAL
Intervention: HABITs + Texts
Number of subjects: 160

Group type: COMPARATOR
Intervention: HABITs
Number of subjects: 160
Study: 39563457

Group type: EXPERIMENTAL
Intervention: J8-K4S2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: p*17-K4S2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparator (rabies vaccine)
Number of subjects: 30
Study: 39563465

Group type: EXPERIMENTAL
Intervention: FC-FORT intervention (7 consecutive weeks of virtual group therapy and homework)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FC-FORT intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist control (care as usual)
Number of subjects: 36
Study: 39563886

Group type: EXPERIMENTAL
Intervention: Targeted therapies based on signaling pathways (e.g., BCR, PI3K/AKT/mTOR, NF-kB, JAK/STAT)
Number of subjects: 0
Study: 39564145

Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane ophthalmic drop, 4 times daily for 8 weeks
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Hypotonic saline control, 4 times daily for 8 weeks
Number of subjects: 1217
Study: 39564355

Group type: EXPERIMENTAL
Intervention: Metaverse-based multimodal rehabilitation intervention over a 4-week period
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional care group
Number of subjects: 60
Study: 39565030

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment
Number of subjects: 3608

Group type: COMPARATOR
Intervention: 14 days of antibiotic treatment
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment (per-protocol analysis)
Number of subjects: 3608

Group type: COMPARATOR
Intervention: 14 days of antibiotic treatment (per-protocol analysis)
Number of subjects: 3608
Study: 39565096

Group type: EXPERIMENTAL
Intervention: Nurse-led mobile app (NL-Mapp) intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 90
Study: 39565228

Group type: COMPARATOR
Intervention: Secukinumab (SEC) 300 mg s.c. administered regularly until week 16, followed by randomization to SEC or placebo up to week 32.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo after SEC treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab (SEC) treatment.
Number of subjects: 0
Study: 39565276

Group type: EXPERIMENTAL
Intervention: High-Intensity Inspiratory Muscle Training (Hi-IMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham Low-Intensity Inspiratory Muscle Training (Lo-IMT)
Number of subjects: 90
Study: 39565449

Group type: EXPERIMENTAL
Intervention: Lactoferrin (100 mg/day for 4 weeks or until discharge)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 39565495

Group type: EXPERIMENTAL
Intervention: Vepdegestrant 200 mg once daily (QD)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vepdegestrant 200 mg QD
Number of subjects: 6
Study: 39565523

Group type: EXPERIMENTAL
Intervention: EORTC QLU-C10D
Number of subjects: 435

Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 435
Study: 39565570

Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab plus radium-223
Number of subjects: 21

Group type: COMPARATOR
Intervention: Radium-223 alone
Number of subjects: 21
Study: 39565635

Group type: EXPERIMENTAL
Intervention: ATEV (Acellular Tissue Engineered Vessel)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Synthetic graft benchmarks
Number of subjects: 86
Study: 39565703

Group type: EXPERIMENTAL
Intervention: Mandala coloring for a minimum of 30 minutes during and after chemotherapy treatment.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no mandala coloring).
Number of subjects: 38
Study: 39565757

Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 39565905

Group type: EXPERIMENTAL
Intervention: Avalus bioprosthesis
Number of subjects: 1132
Study: 39565908

Group type: EXPERIMENTAL
Intervention: Grade 1-2 treatment-related irAEs
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Grade 3-4 treatment-related irAEs
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Grade 1-2 dermatologic toxicity
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Grade 1-2 fatigue, gastrointestinal, metabolic, hepatic, endocrine, and thyroid toxicities
Number of subjects: 684
Study: 39565980

Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization (adjunct to standard treatment)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 310
Study: 39565990

Group type: EXPERIMENTAL
Intervention: GA2
Number of subjects: 20

Group type: COMPARATOR
Intervention: GA1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 39565989

Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization with liquid embolic material
Number of subjects: 722

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 722
Study: 39565987

Group type: EXPERIMENTAL
Intervention: Couple-based genetic carrier screening
Number of subjects: 10038
Study: 39565988

Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization plus surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 400
Study: 39566036

Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration (total sleep time; TST)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sleep timing (sleep onset and offset time)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sleep quality (wake after sleep onset; WASO)
Number of subjects: 48
Study: 39566048

Group type: EXPERIMENTAL
Intervention: YACHT program
Number of subjects: 42
Study: 39566051

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-Control
Number of subjects: 0
Study: 39566053

Group type: EXPERIMENTAL
Intervention: Community-based testing with direct in-home assessments
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Facility-based testing with subsequent referral
Number of subjects: 6000
Study: 39566056

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39566128

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Promestriene treatment (Control)
Number of subjects: 62
Study: 39566293

Group type: EXPERIMENTAL
Intervention: Anatomy-Based Fitting (ABF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Default Fitting (DF)
Number of subjects: 20
Study: 39566404

Group type: EXPERIMENTAL
Intervention: Yangxinshi
Number of subjects: 681

Group type: COMPARATOR
Intervention: Trimetazidine
Number of subjects: 681
Study: 39566464

Group type: EXPERIMENTAL
Intervention: Durvalumab with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39566467

Group type: EXPERIMENTAL
Intervention: Autologous P63 transplantation
Number of subjects: 0
Study: 39566600

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) - 75 g carbohydrates for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-fat diet (LED) - 180 g carbohydrates for 8 weeks
Number of subjects: 55
Study: 39566722

Group type: EXPERIMENTAL
Intervention: STEPP intervention (five-session, phone-delivered peer support)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: STEPP intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual transplant care (control)
Number of subjects: 90
Study: 39566872

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 39566948

Group type: EXPERIMENTAL
Intervention: Chiropractic care plus usual medical care
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual medical care alone
Number of subjects: 750
Study: 39566954

Group type: EXPERIMENTAL
Intervention: MdF's comprehensive intervention programme
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care in sociomedical structures
Number of subjects: 360
Study: 39566994

Group type: EXPERIMENTAL
Intervention: Transfer of care to adult healthcare
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Negative care experiences after transfer of care
Number of subjects: 440
Study: 39567210

Group type: EXPERIMENTAL
Intervention: IO-108 monotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IO-108 + pembrolizumab
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IO-108 monotherapy and combination therapy
Number of subjects: 25
Study: 39567211

Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa monotherapy (6 µg/kg/day)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa with pembrolizumab
Number of subjects: 243

Group type: COMPARATOR
Intervention: Nemvaleukin alfa (dose-escalation)
Number of subjects: 243
Study: 39567374

Group type: EXPERIMENTAL
Intervention: GET-WEL Program (Group-based Telehealth behavioral Weight Loss)
Number of subjects: 24
Study: 39567430

Group type: EXPERIMENTAL
Intervention: Percutaneous consolidation (cementoplasty, screw fixation, or both)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Percutaneous consolidation
Number of subjects: 138
Study: 39567910

Group type: EXPERIMENTAL
Intervention: Goat milk-based formula (GMF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cow's milk-based formula (CMF)
Number of subjects: 56
Study: 39567939

Group type: EXPERIMENTAL
Intervention: Family members' experiences and roles during rehabilitation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Typologies of family members' roles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perceptions of involvement in rehabilitation process
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Health considerations by healthcare professionals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Impact of family members' perceptions on well-being
Number of subjects: 20
Study: 39567961

Group type: EXPERIMENTAL
Intervention: Unilateral brief-pulse ECT
Number of subjects: 36

Group type: COMPARATOR
Intervention: Untreated healthy controls
Number of subjects: 36
Study: 39568009

Group type: EXPERIMENTAL
Intervention: Modified Kasai operation combined with autologous bone marrow mononuclear cell (BMMNC) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified Kasai operation
Number of subjects: 20
Study: 39568042

Group type: EXPERIMENTAL
Intervention: Fecal carriage of carbapenem-resistant gram-negative bacteria (CR-GNB)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isolation of CR-GNB from stool
Number of subjects: 150
Study: 39568547

Group type: EXPERIMENTAL
Intervention: Hatha yoga, practiced 3 times a week for 8 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 98
Study: 39568632

Group type: EXPERIMENTAL
Intervention: Hockey Fans in Training (Hockey FIT) intervention
Number of subjects: 997

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 997

Group type: COMPARATOR
Intervention: Difference between intervention and control
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Non-study related serious adverse events
Number of subjects: 997
Study: 39568724

Group type: EXPERIMENTAL
Intervention: 18 g sunflower lecithin (LPL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 g oat polar lipids (OPL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 18 g rapeseed oil (RSO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference white wheat bread (WWB)
Number of subjects: 18
Study: 39568790

Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% 5-Fluorouracil (5FU) cream
Number of subjects: 12
Study: 39569196

Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP) with emtricitabine-tenofovir (FTC-TDF) or emtricitabine-tenofovir alafenamide (FTC-TAF)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 144
Study: 39569316

Group type: EXPERIMENTAL
Intervention: Integrated care from cardiologists, nephrologists, endocrinologists, and specialist nurses at an integrated clinic
Number of subjects: 131

Group type: COMPARATOR
Intervention: Traditional care from separate specialists
Number of subjects: 131
Study: 39569437

Group type: EXPERIMENTAL
Intervention: Creatine with guanidinoacetic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39569450

Group type: EXPERIMENTAL
Intervention: Inpatient renourishment (25.10 ± 19.73 days)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Stool energy content at discharge (AN-DIS: 5.72 ± 0.86 kcal/g)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Weight and BMI at admission and discharge
Number of subjects: 103

Group type: COMPARATOR
Intervention: Non-eating disorder controls (non-ED)
Number of subjects: 103
Study: 39569496

Group type: EXPERIMENTAL
Intervention: MRI-proven incident ischemia (defined as recurrent ischemic stroke or at least 1 incident lacune or incidental diffusion-weighted imaging-positive lesion on brain MRI at 6 months)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: MRI-proven incident ischemia
Number of subjects: 249
Study: 39569505

Group type: EXPERIMENTAL
Intervention: Removable leadless pacemakers
Number of subjects: 117

Group type: COMPARATOR
Intervention: Nonremovable leadless pacemakers
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional transvenous pacemakers
Number of subjects: 117
Study: 39569542

Group type: EXPERIMENTAL
Intervention: Patient-administered audio recordings
Number of subjects: 50
Study: 39569553

Group type: EXPERIMENTAL
Intervention: Govorestat (AT-007)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 39569560

Group type: EXPERIMENTAL
Intervention: More MVPA (Moderate to Vigorous Physical Activity) relative to LPA (Light Physical Activity) and sedentary time
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: More LPA relative to MVPA and sedentary time
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Increasing sedentary time or engaging in MVPA at the expense of LPA during childcare
Number of subjects: 107
Study: 39569704

Group type: EXPERIMENTAL
Intervention: Caregiver-implemented imitation measures delivered with support from a remote virtual assessor
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Caregiver-implemented intervention delivered through the Part C early intervention (EI) system
Number of subjects: 177
Study: 39569806

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (asymmetric biphasic rectangular waveforms) applied to the common fibular nerve compartment of the sciatic nerve.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Electrical stimulation (asymmetric biphasic rectangular waveforms) applied to the tibial nerve compartment of the sciatic nerve.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (common fibular and tibial nerve compartments)
Number of subjects: 38
Study: 39570031

Group type: EXPERIMENTAL
Intervention: S315 (480 mg, 960 mg, 1920 mg, 3840 mg, 7680 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: S315 (various doses)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: S315
Number of subjects: 41
Study: 39570078

Group type: EXPERIMENTAL
Intervention: Anticoagulant
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Antiplatelet
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control (no competing LAA mechanisms)
Number of subjects: 501
Study: 39570213

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 168
Study: 39570234

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study: 39570238

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Symptoms Questionnaire (AFSQ)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Electrocardiography documented AF
Number of subjects: 267
Study: 39570242

Group type: EXPERIMENTAL
Intervention: Amulet occluder
Number of subjects: 1878

Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 1878
Study: 39570246

Group type: EXPERIMENTAL
Intervention: TriClip
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study: 39570303

Group type: EXPERIMENTAL
Intervention: Frail patients (Edmonton Frail Scale REFS values ≥8)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Sarcopenic patients
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Myosteatotic patients
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 194
Study: 39570398

Group type: EXPERIMENTAL
Intervention: Radiolabeled probes targeting prostate-specific membrane antigen (PSMA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hybrid PET/MRI system
Number of subjects: 12
Study: 39570545

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 5089
Study: 39570583

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (group 2)
Number of subjects: 530

Group type: COMPARATOR
Intervention: FOLFOX/FOLFIRI plus bevacizumab (group 1)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: FOLFOX/FOLFIRI plus panitumumab (group 4)
Number of subjects: 530

Group type: COMPARATOR
Intervention: FOLFOX/FOLFIRI plus bevacizumab (group 3)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 530
Study: 39570589

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparotomy (Control)
Number of subjects: 100
Study: 39570588

Group type: EXPERIMENTAL
Intervention: Hearing intervention (provision of hearing aids and related technologies, counseling, education)
Number of subjects: 977

Group type: COMPARATOR
Intervention: Health education control (individual sessions covering topics relevant to chronic disease, disability prevention)
Number of subjects: 977
Study: 39570590

Group type: EXPERIMENTAL
Intervention: High-frequency follow-up testing (CT scans and CEA screening at 6, 12, 18, 24, and 36 months after surgery); 1227 patients.
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Low-frequency follow-up testing (CT scans and CEA screening at 12 and 36 months after surgery); 1229 patients.
Number of subjects: 2509
Study: 39570620

Group type: EXPERIMENTAL
Intervention: Olverembatinib 30 mg every other day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Olverembatinib 40 mg every other day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Olverembatinib 50 mg every other day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prior ponatinib treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prior asciminib resistance
Number of subjects: 80
Study: 39570681

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study: 39570688

Group type: EXPERIMENTAL
Intervention: Strengths use
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stress
Number of subjects: 120

Group type: COMPARATOR
Intervention: Depression
Number of subjects: 120